- Conditions
- Portal Hypertension, TIPS
- Interventions
- BD Liverty™ TIPS Stent Graft
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 8,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cervical Myelopathy, Hip Fractures
- Interventions
- Cervical MRI, History & Physical Exam
- Diagnostic Test · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Fishers, Indiana • Indianapolis, Indiana
- Conditions
- Vitiligo
- Interventions
- Ruxolitinib cream, Vehicle cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
- Interventions
- Sodium Fusidate, Placebo
- Drug
- Lead sponsor
- Aceragen
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 25
- States / cities
- Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Mixed Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Ovarian Neoplasm, Malignant Ovarian Serous Tumor, Malignant Ovarian Transitional Cell Tumor, Ovarian Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 131
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
- Conditions
- Primary Biliary Cirrhosis (PBC)
- Interventions
- Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 16 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 242
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 189 more
- Conditions
- Ischemic Stroke, Transient Ischemic Attack
- Interventions
- Physician stroke guideline adherence, Stroke Self Management, Attention Control Group
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Houston, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- Aztreonam for Inhalation Solution (AZLI)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
- Conditions
- Prostate Cancer
- Interventions
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Ischemic Stroke, Systemic Embolism
- Interventions
- AtriClip LAA Exclusion System
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 102
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more
- Conditions
- Chronic Kidney Disease
- Interventions
- grain (soy) protein diet, casein (meat) protein diet
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Interventions
- N-Acetyl Cysteine, sugar pill
- Drug · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 16 Years to 35 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab, Dexamethasone, Venetoclax
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Rochester, Minnesota • Wauwatosa, Wisconsin
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 308
- States / cities
- Little Rock, Arkansas • Fullerton, California • Orange, California + 219 more
- Conditions
- Sleep Hygiene, Inadequate
- Interventions
- Problematic bedtime media use counseling, Sleep problem counseling
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
- Interventions
- Screening Mammography, Biospecimen Collection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 514
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Glendale, Arizona + 341 more
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Enfortumab Vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Orange, California • Stanford, California + 18 more
- Conditions
- Asthma
- Interventions
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
- Conditions
- Ovarian Cancer
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 31
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Chlamydia Trachomatis, Gonorrhea
- Interventions
- Not listed
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 1,766 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 15 more
- Conditions
- Premature Birth
- Interventions
- Prophylactic Delivery Room Continuous Positive Airway Pressure
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Minute to 5 Minutes
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Oklahoma City, Oklahoma
- Conditions
- Atrial Fibrillation
- Interventions
- Endoscopic Ablation System, Standard Anti-arrhythmic Drug (AAD) Therapy
- Device · Drug
- Lead sponsor
- CardioFocus
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 15 more